First Time Loading...

Laboratory Corporation of America Holdings
NYSE:LH

Watchlist Manager
Laboratory Corporation of America Holdings Logo
Laboratory Corporation of America Holdings
NYSE:LH
Watchlist
Price: 216.57 USD 1.43% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. [ Read More ]

The intrinsic value of one LH stock under the Base Case scenario is 226.61 USD. Compared to the current market price of 216.57 USD, Laboratory Corporation of America Holdings is Undervalued by 4%.

Key Points:
LH Intrinsic Value
Base Case
226.61 USD
Undervaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Laboratory Corporation of America Holdings

Backtest LH Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Company Forecasts Revenue Growth Despite Challenges
2023-Q4 Earnings Call

Company Forecasts Revenue Growth Despite Challenges

The company posted a quarter revenue of $2.3 billion, a marginal 2.6% rise from the previous year, attributed to 0.8% organic growth and 1.8% through acquisitions. Despite a steep 73% drop in COVID testing revenue, the Base Business saw organic growth of 5.7%. Diagnostic operating income fell to $354 million from $387 million, largely due to the lower COVID testing, while the Biopharma segment's income improved to $109 million. Looking ahead, the company anticipates Enterprise revenue growth of 4.7% to 6.5% for 2024, driven by expectations of free cash flow redeployment into acquisitions, share buybacks, and dividends.

Financials

Balance Sheet Decomposition
Laboratory Corporation of America Holdings

Current Assets 3.8B
Cash & Short-Term Investments 536.8m
Receivables 2.1B
Other Current Assets 1.1B
Non-Current Assets 13B
Long-Term Investments 26.9m
PP&E 2.9B
Intangibles 9.5B
Other Non-Current Assets 536.5m
Current Liabilities 3.2B
Accounts Payable 827.5m
Accrued Liabilities 969.8m
Other Current Liabilities 1.4B
Non-Current Liabilities 5.6B
Long-Term Debt 4.1B
Other Non-Current Liabilities 1.5B
Efficiency

Earnings Waterfall
Laboratory Corporation of America Holdings

Revenue
12.2B USD
Cost of Revenue
-8.8B USD
Gross Profit
3.4B USD
Operating Expenses
-2.2B USD
Operating Income
1.1B USD
Other Expenses
-705.7m USD
Net Income
418m USD

Free Cash Flow Analysis
Laboratory Corporation of America Holdings

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

LH Profitability Score
Profitability Due Diligence

Laboratory Corporation of America Holdings's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Positive 3-Year Average ROE
Positive Operating Income
51/100
Profitability
Score

Laboratory Corporation of America Holdings's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

LH Solvency Score
Solvency Due Diligence

Laboratory Corporation of America Holdings's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
46/100
Solvency
Score

Laboratory Corporation of America Holdings's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LH Price Targets Summary
Laboratory Corporation of America Holdings

Wall Street analysts forecast LH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LH is 251.94 USD with a low forecast of 222.2 USD and a high forecast of 283.5 USD.

Lowest
Price Target
222.2 USD
3% Upside
Average
Price Target
251.94 USD
16% Upside
Highest
Price Target
283.5 USD
31% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LH Price
Laboratory Corporation of America Holdings

1M 1M
+1%
6M 6M
+7%
1Y 1Y
-2%
3Y 3Y
-13%
5Y 5Y
+46%
10Y 10Y
+124%
Annual Price Range
216.57
52w Low
197.69
52w High
234.91
Price Metrics
Average Annual Return 14.87%
Standard Deviation of Annual Returns 27.06%
Max Drawdown -47%
Shares Statistics
Market Capitalization 18.2B USD
Shares Outstanding 84 100 000
Percentage of Shares Shorted 3.44%

LH Return Decomposition
Main factors of price return

What is price return decomposition?

LH News

Other Videos

Company Profile

Laboratory Corporation of America Holdings Logo
Laboratory Corporation of America Holdings

Country

United States of America

Industry

Health Care

Market Cap

18.2B USD

Dividend Yield

1.35%

Description

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. The company is headquartered in Burlington, North Carolina and currently employs 75,500 full-time employees. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The firm also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The firm serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers. The company also helps in delivering non-clinical testing services.

Contact

NORTH CAROLINA
Burlington
358 S Main St
+13362291127.0
https://www.labcorp.com

IPO

1991-04-24

Employees

75 500

Officers

President, CEO & Chairman
Mr. Adam H. Schechter
CFO & Executive VP
Mr. Glenn A. Eisenberg
Executive VP, President of Diagnostics Laboratories & COO
Mr. Mark S. Schroeder
EVP, President of Early Development Research Laboratories & Chief Medical Officer
Dr. Brian J. Caveney J.D., M.D., M.P.H.
Senior VP & Chief Accounting Officer
Mr. Peter J. Wilkinson
Executive VP and Chief Information & Technology Officer
Mr. Lance V. Berberian
Show More
Chief Scientific Officer & Senior VP
Dr. Marcia T. Eisenberg Ph.D.
Vice President of Investor Relations
Christin O'Donnell
Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Sandra D. van der Vaart
Executive VP & Chief Marketing Officer
Ms. Amy B. Summy
Show Less

See Also

Discover More
What is the Intrinsic Value of one LH stock?

The intrinsic value of one LH stock under the Base Case scenario is 226.61 USD.

Is LH stock undervalued or overvalued?

Compared to the current market price of 216.57 USD, Laboratory Corporation of America Holdings is Undervalued by 4%.